Cardiac involvement is common in acromegaly, but the prevalence of valvular abnormalities in patients with acromegaly has not been documented, and was topic of the current study.
Introduction
Acromegaly is associated with increased cardiac morbidity and mortality.
Recogniz ed manifestations of cardiac disease in this population include chronic heart failure (CHF) due to either global systolic dysfunction (cardiomyopathy) or to diastolic dysfunction with preserved systolic function. The pathophysiology of these cardiac complications of acromegaly is incompletely understood. It has been hypothesiz ed that abnormal extracellular matrix regulation by overproduction of growth hormone (GH) or IGF-1 in patients with acromegaly may contribute to both systolic and diastolic myocardial dysfunction (1) . In addition, GH can increase circulating pro-inflammatory cytok ine levels, lik e IL-1-beta and TNF-alpha (2). These cytok ines, in turn, increase gene expression of matrix metalloproteinases (MMPs) , that are capable of altering the composition of the extracellular matrix (3). These abnormalities in matrix regulation are associated with cardiac chamber dilation and reduced myocardial tensile strength (4). Abnormalities in matrix regulation have also been implicated in the pathogenesis of aortic and mitral valve disease (5-7) the latter of which is manifest as thick ened and redundant valves which are incompetent and have an appearance of myxoid degeneration on pathology.
We hypothesiz ed that patients with acromegaly, in whom GH and IGF-1 are pathologically elevated, have an increased incidence of clinically relevant aortic and mitral valve disease. There are anecdotal reports of aortic or mitral valve operations performed in patients with acromegaly that support this concept (8, 9) . However, the prevalence of valvular abnormalities in patients with acromegaly has not been documented.
Therefore, we prospectively evaluated the prevalence of valvular abnormalities in patients with acromegaly and no prior history of cardiac disease.
Methods

Patients and controls
In a prospective study design, 40 patients (19 male and 21 female) with acromegaly were studied. The median age of the patients was 57 years (range 20-83 yrs). Nine patients were untreated (de novo patients), and 31 patients were treated either by transphenoidal surgery (n=23) or by primary medical treatment (n=8) ( Table 1 ). 
Echocardiography, Data Acquisition
Patients were imaged in the left lateral decubitus position using a commercially available system (Vingmed system FiV e, General Electric mild, moderate or severe, using previously described methods (11, 12) .
Significant valvular disease was determined using the FDA case definition: mild or greater aortic regurgitation or mitral regurgitation equal or more than moderate severity (13) .
Hormone assays
GH concentrations were quantitated in duplicate using a sensitive timeresolved immunofluorescent assay (Wallac Oy, Turku, Finland), specific for 22 kDA GH protein. The detection limit was 0.03 mU/l (0.01 ì g/L).
Intra-assay coefficients of variation were 1.6-8.4% in the GH-range 0.1-18 ìg/L (0.26-47 mU/L). The total serum IGF-1 concentration was determined by radioimmunoassay (RIA) after extraction and purification on ODS-silica columns (Incstar corp., Stillwater, MN, USA). The interassay coefficient of variation was less than 11%. The detection limit was 1.5 nmol/l). Age related normal data were determined in the same laboratory. IGF-1 was also expressed as a standard deviation score form age-related normal levels.
Statistical analysis
Student s t-test was used for continuous variables. The Chi-square test and the Cochrane-Mantell test were used to compare continuous and categorical data to detect trends. Binary logistic regression stepwise was performed to explore possible determinants of valvular disease.
SPSS software version 10.0 (Inc, Chicago, USA) was used. Differences were considered statistically significant at the p<0.05 level.
78 Table 1 . P atients Characteristics
Left ventricular systolic function and dimensions in acromegalic patients
were within the normal range (see Table 2 ). However, ten patients (25%) Table 3 . V alvular regurgitation in acromegalic patients ( n= 40) compared to controls ( n= 1 2 0) .
Chapter 4
Tricuspid valve regurgitation was detectable in 28% (11/40) of the patients vs 50% (60/120) of control subjects. However, pathological tricuspid regurgitation (moderate or severe according to the FDA criteria) was absent in all patients and present in only 3% (3/120) of control subjects. This difference was not significantly different.
Valvular regurgitation of one valve was present in ten patients, valvular regurgitation of two valves in two patients, and valvular regurgitation of three valves in two patients.
Prevalence rates of valvular abnormalities were similar between active and inactive patients. To explore other possible determinants of valvular disease, binary logistic regression analysis with a stepwise approach was performed.
Determinants of valvular disease
The following parameters were analyzed: IGF-1 and GH concentrations at time of diagnosis, age, active-vs inactive disease, (previous) treatment with octreotide, and the presence of hypertension. No significant correlations were found for any of the above mentioned parameters.
Increased valvular regurgitation in acromegaly
Discussion
This study clearly demonstrates that in patients with acromegaly, valvular abnormalities are more prevalent than in control subjects, who were individually matched for left ventricular function, age, sex, and the presence of hypertension. Moreover, we are the first to show that the prevalence of valvular disease in acromegaly proves to be highly significantly correlated to the duration of the disease.
In this study, we compared echocardiographic data in patients with acromegaly with active or inactive disease to a control data base.
Matched data base analysis is necessary due to the relatively high prevalence of mild valvular abnormalities in the general population, which tends to increase with age. Studies using 2D color doppler echocardiography with a semiquantitative methods for estimating the severity of regurgitation from trace to severe, have demonstrated that the population-based prevalence of minimal or mild mitral and tricuspid valve regurgitation was quite high (58-77%), whereas aortic valve regurgitation was much less prevalent (14, 15) . Accordingly, the United States Food and Drug Administration (FDA) has defined pathological regurgitation of the mitral and tricuspid valve as more than or equal to moderate severity, and pathological regurgitation of the aortic valve as more than or equal to mild severity. However, in the normal offspring in the Framingham Heart Study (14) , trace severity for mitral and tricuspid valve was present in 75% of the subjects and independent on age, whereas trace aortic regurgitation was only present in about 5% of subjects and strongly dependent on age (from about 2% at the age of 26-39 years to about 10% at the age of 70-83 years). Therefore, it has been postulated, that the FDAs criteria for aortic regurgitation may be too narrow, and the case definition for pathologic regurgitation may need to be modified or made age specific (15) . In our study, we therefore individually matched each acromegalic patient for age, sex and the presence of hypertension, to three non acromegalic control subjects.
We observed prevalence rates of any and significant valvular regurgitation in these 120 control subjects comparable to those reported in the normal offspring in the Framingham Heart Study. Aortic regurgitation (present in 13% of men and 8% of women in the Framingham Heart Study) was present in 7% of our control subjects, vs in 30% of our patients with acromegaly. However, the abnormalities detected were predominantly mitral regurgitation of trace severity. This is due to the temporal/spatial high resolution of the echo equipment available (GE vivid 7, Vingmed system FiVe).
The pathogenesis of myxomatous heart valve degeneration remains uncertain. Rabkin and co-workers (6), proposed a model in which activation of interstitial cardiac valve cells leads to the release of proteolytic enzymes, phenotypic modulation, and proliferation.
Subsequently, degradation of collagen, elastin fragmentation, and glycosaminoglycans accumulation produces extracellular matrix remodeling, and characteristic leaflet myxomatous thickening and redundancy. However, the primary stimulus for activation of these resting fibroblast-like interstitial cells remains to be elucidated, but mechanical stress and genetic abnormalities are proposed to play a key role. In our three patients who underwent valve replacement surgery, similar It is interesting to note that all patients in whom valvular abnormalities were detected, had normal LV function and that 85% (17/20) of these patients also had normal dimensions. This suggests that valvular disease duration was brief for most patients. The discrepancy between the relative lack of cardiomyopathic responses in most patients in our study compared to the recently published study of Colao et al.(19) is striking, even though we found similar rates of regurgitant valve disease.
However, considering the fact that 57% of our patients had been adequately controlled for a long time by octreotide therapy, and that they had similar prevalence rates of regurgitant valve disease as those without octreotide treatment, the following notion emerges. Octreotide is known to reverse the development of LVH (22) . However, apparently, this was not reflected in a lower rate of regurgitant valve disease. In line with this notion we found fibrinoid changes in the valves that were removed. These changes are in other diseases associated with irreversible valve disease. Based on the comparison of the data of Colao, et al. (19) and our study, we hypothesize that regurgitant valvular disease in acromegaly may be less amnedable to therapeutic intervention aimed at reducing excessive GH secretion than myocardial complications of acromegaly.
In conclusion, we are the first to report that acromegaly is associated with an increased prevalence of regurgitant valvular heart disease, which is dependent of the duration of exposure to increased growth hormone concentrations, and which is not associated with impaired left ventricular function nor hypertension. This increased likelihood of valve disease may impact the cardiac surveillance of patients with acromegaly and could provide us more insight on the basic pathophysiological interactions of growth hormone with connective tissues. The increased prevalence of occult valve disease implicates that these patients require appropriate follow-up care and monitoring, especially those with inadequate control of GH overproduction. Moreover, antibiotic prophylaxis for any non-sterile procedures may be required.
